Sofinnova Partners closed oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand […]
Oslo, Norway – 30 September 2026 – Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that three abstracts from its Radspherin® program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) […]
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s disease AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, announced that it has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug […]
Hansa Biopharma appointed Adam Cutler as new Chief Financial Officer Hansa Biopharma AB announced the appointment of Adam Cutler as its new Chief Financial Officer (CFO) and member of the Executive Committee, effective June 22, 2026. Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June […]
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
